Liquim Limited is pleased to announce that our Respi-Viva Nasal Spray and Respi-Viva Oral spray have been entered on the TGA’S ARTG Register of Listed medicines under the numbers AUST L 399835 and AUST L 399836, respectively.
These two newly listed medicine products result from research and the development of nasal and oral sprays for the maintenance and support of nasal and oral mucosa and the upper respiratory tract. The permitted indications for Respi-Viva Nasal Spray are “Maintain / Support healthy mucous membranes / mucous tissue of the respiratory tract and Soothe respiratory tract mucous membranes / mucous tissue”, whilst the permitted indications for Respi-Viva Oral spray include ‘Maintain / Support oral mucous membrane health”.
Both products Respi-Viva Nasal Spray and Respi-Viva Oral Spray are alcohol (ethanol)-free and contain plant-derived ingredients which are on the TGA lists of products deemed safe for human consumption
Neither product is yet available for sale in Australia. The company is finalising manufacturing agreements with an international cGMP manufacturer and expects that product will ship in Q2 2023.